Sax Wealth Advisors LLC Invests $646,000 in Zoetis Inc. $ZTS

Key Points

• Sax Wealth Advisors LLC has acquired a new position in Zoetis Inc., investing approximately $646,000 for 3,921 shares during the first quarter.
• Institutional investors and hedge funds have significant stakes in Zoetis, owning 92.80% of the company's stock, with several institutions making substantial investments in the first quarter.
• Zoetis reported $1.76 earnings per share for the last quarter, exceeding estimates and marking a 4.2% increase in revenue compared to the previous year.

Sax Wealth Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,921 shares of the company's stock, valued at approximately $646,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nuveen LLC acquired a new position in Zoetis during the first quarter worth $616,375,000. Sarasin & Partners LLP acquired a new position in Zoetis during the first quarter worth $339,111,000. Mackenzie Financial Corp grew its holdings in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after acquiring an additional 1,782,110 shares during the period. GAMMA Investing LLC grew its holdings in Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after acquiring an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC grew its holdings in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Zoetis Stock Up 0.5%

ZTS opened at $156.3180 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $69.28 billion, a P/E ratio of 26.91, a PEG ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business's fifty day simple moving average is $153.84 and its 200 day simple moving average is $158.52.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZTS. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.